Results 71 to 80 of about 160,832 (337)

Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition

open access: yesNeoplasia: An International Journal for Oncology Research, 2012
Checkpoint kinase 1 (Chk1) inhibition sensitizes pancreatic cancer cells and tumors to gemcitabine. We hypothesized that Chk1 inhibition would sensitize pancreatic cancer stem cells to gemcitabine.
Venkatasubbaiah A. Venkatesha   +8 more
doaj   +1 more source

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction

open access: yesFrontiers in Pharmacology, 2022
Pancreatic cancer is an aggressive cancer characterized by high mortality and poor prognosis, with a survival rate of less than 5 years in advanced stages. Ivermectin, an antiparasitic drug, exerts antitumor effects in various cancer types.
Da Eun Lee   +16 more
doaj   +1 more source

Tumor‐Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells

open access: yesAdvanced Science, EarlyView.
This study demonstrates that tumor‐derived IL‐35 promotes pancreatic cancer fibrosis by indirectly activating pancreatic stellate cells through IGFBP2/IGF‐1R/PI3K‐Akt and Tsp‐1/TGF‐β pathways. IL‐35 blockade reduces stromal fibrosis, restores chemosensitivity, and synergizes with gemcitabine‐based regimens, highlighting IL‐35 as a promising therapeutic
Hui Li   +14 more
wiley   +1 more source

mTORC2 signaling drives the development and progression of pancreatic cancer [PDF]

open access: yes, 2016
mTOR signaling controls several critical cellular functions and is deregulated in many cancers, including pancreatic cancer. To date, most efforts have focused on inhibiting the mTORC1 complex.
Bardeesy, Nabeel   +17 more
core   +1 more source

Targeting Mast Cell Activation and MIF‐Mediated Remodelling Enhances Chemotherapy Response in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
Neoadjuvant gemcitabine plus nab‐paclitaxel (AG) reprograms pancreatic ductal adenocarcinoma by shifting malignant cells toward a classical phenotype and remodeling the tumor microenvironment. Despite enhancing cytotoxic NKT cells, AG activates tumor‐associated mast cells (TAMCs) and inflammatory CAFs through MIF signaling.
Libo Wang   +16 more
wiley   +1 more source

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

open access: yesHepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu   +11 more
wiley   +1 more source

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS

open access: yesJurnal Urologi Indonesia, 2019
Objective: To determine the differences of apoptosis effect between the combination of meloxicam and gemcitabine-carboplatin compared to gemcitabine-carboplatin alone as the standard of chemotherapy care in urothelial carcinoma culture cells.
Ananta Cahyo Nugroho   +3 more
doaj   +1 more source

A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. [PDF]

open access: yesPLoS ONE, 2013
Gemcitabine is among the most efficacious and widely used antimetabolite agents. Its molecular targets are ribonucleotide reductase M1 (RRM1) and elongating DNA.
Jun Zhou   +6 more
doaj   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

open access: yes, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis   +10 more
core   +1 more source

A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

open access: yesAdvanced Science, EarlyView.
LZU‐WZLYCS01 is a novel FGFR3‐targeting ADC for bladder cancer with 7‐ethyl‐9‐fluorocamptothecin (A2) as its cytotoxic payload. LZU‐WZLYCS01 intracellularly releases A2, which targets MAD2L1 to activate the cGAS‐STING pathway and induce tumor cell apoptosis.
Shu Cui   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy